Publikation

Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): Coincidence, Association or Mimicry?

Wissenschaftlicher Artikel/Review - 21.02.2022

Bereiche
Kontakt

Zitation
Kluckert J, Brutsche M. Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): Coincidence, Association or Mimicry?. Annals of Clinical Case Reports 2022; 7
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Annals of Clinical Case Reports 2022; 7
Veröffentlichungsdatum
21.02.2022
eISSN (Online)
2474-1655
Verlag
Remedy Publications LLC. (Belmont, California)
Kurzbeschreibung/Zielsetzung

Clinical Image
A 70-year old patient with longstanding history of sarcoidosis (initially ATS- stage II), presented
with progressive dyspnea and dry cough. Although corticosteroid therapy initially improved lung
function, a decline (Figure 1) was observed. Thoracic CT-scan was compatible with definite unusual
interstitial pneumonia potentially engrafted on the preexisting sarcoidosis. After multidisciplinary
discussion antifibrotic therapy with Nintedanib was started. Lung function and fibrosis on the
CT-scan improved (Figure 1, 2). Collins et al. [1] found a series of cases and coined the term
“Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis CSIPF”. IPF is defined as fibrosis
without inflammation and sarcoidosis as a multisystem chronic inflammatory condition – these supposedly being two distinct entities [2,3]. Did we experience
coincidence, association or mimicry between these two entities?
Lucky enough antifibrotic treatments is also licensed for progressive
non-IPF fibrotic lung diseases.